Leerink Swann downgrades Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Market Perform.

Leerink analyst says, "Our thesis on VRX is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE